
    
      The clinical trial is multi-centre, national, Phase 2, open-label, single-arm. The primary
      objective of this study is to assess, in HCV genotype 4-infected patients in failure to prior
      treatment with pegylated Interferon and Ribavirin bitherapy, the rate of sustained
      virological response (SVR) 12 weeks after 12 weeks of treatment with an all-oral combination
      of 3 DAAs in a Fixed-Dose-Combination (Asunaprevir 200 mg, Daclatasvir 30 mg and BMS - 791325
      75 mg) twice a day.

      Estimated enrollment is 60 patients during the enrolment period (9 months).

      Schedule of assessments:

      w4-w8 : screening D0 : Start of anti-HCV tritherapy (Asunaprevir + Daclatasvir + BMS-791325)
      w12: stop tritherapy w24: Sustained virological response SVR12 assessment (12 weeks post
      treatment) w36 : Sustained virological response SVR24 assessment (24 weeks post treatment)
    
  